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Abstract
Gene therapy is a targeted therapy which can be used in the treatment of various acquired 
and inherited diseases. Inhabitation of a gene function, restoring or improving a gene, or 
gaining a new function can be achieved by gene therapy strategies. The most crucial step 
in this therapy is delivering the therapeutic material to the target. Nanosized calcium 
phosphates (CaPs) have been considered as promising carriers due to their excellent bio-
compatibility. In this chapter, the delivery of DNA, siRNA, and miRNA by using CaP 
nanocarriers were compiled in detail and the main parameters which can affect the car-
rier properties and thus the gene transfer efficiency were also discussed.
Keywords: calcium phosphate nanoparticles, non-viral vector, hydroxyapatite, gene 
therapy, gene silencing
1. Introduction
Recently, targeted therapies are becoming more attractive since they do not harm healthy cells 
and have high selectivity. Gene therapy is the modification of patients’ cells genetically for cur-
ing or making the health state better. With gene therapy strategies, one gene function can be 
inhibited, restored or improved or a new function can be gained. For an improvement in func-
tional disorders induced by the mutation or to inhibit the expression of an inadequate gene, a 
therapeutic gene material, and its related regulatory components are delivered to the nucleus 
to treat the diseases. In most cases, owing to their negative charge, naked oligonucleotides can-
not penetrate the cell; therefore, an appropriate carrying agent is needed. The most crucial issue 
in gene therapy is delivering the therapeutic gene, which first must overcome the  extracellular 
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barriers and, subsequently, the cellular barriers. The carrier used for loading them is called 
“a vector,” while the vectors recently been used for gene therapy are roughly sorted as viral 
vectors and non-viral vectors. However, viral vectors’ side effects, potential cytotoxicity of the 
carriers, and poor transfection efficiency of non-viral vectors have currently limited the accom-
plishment of gene therapy. As the use of nanoparticles has been a remarkable methodology 
in the solution of a variety of problems, they can be employed as non-viral delivery vehicles 
for oligonucleotides in molecular biology and medicine [1]. With having excellent biocompat-
ibility and high chemical affinity toward DNA and RNA, calcium phosphate nanoparticles 
can participate in the delivery systems which can limit most of the problems in delivering the 
therapeutic molecules to the nucleus of target cells. Further, calcium phosphates can overcome 
the extracellular barriers and then dissolve in the acidic pH within endosomes and lysosomes 
which lead the release of nucleic acids in the targeted region of the cell [2].
This review focuses on the potential employment of hydroxyapatite and other calcium phos-
phate nanoparticles as non-viral vectors in gene therapy and gene silencing as well as empha-
sizing the recent studies to expose the benefits for using such vectors.
2. What is gene therapy?
The genes on the chromosomes are the smallest genetic units that are effective in producing 
vital proteins for the cells. Any mutation that occurs in the genome can cause the disease 
because it changes the protein functions. Gene therapy is basically described as the transfer of 
genetic material with therapeutic effect to specific targeted cells or tissues with minimal toxic-
ity to provide clinical benefits in the treatment of genetic and infectious diseases. Inhabitation 
of a gene function, restoring or improving a gene, or gaining a new function can be achieved 
by gene transfer strategies.
Gene therapy has been quite important in treating the various acquired and inherited diseases 
(e.g., AIDS, cancer, and other genetic disorders). As a theory, if the sequence of a mutant gene 
which is defined as an oncogene is recognized, gene therapy can be used in the treatment of 
any cancer disease. Moreover, its execution in the cure of genetic disorders such as muscu-
lar dystrophy, cystic fibrosis and severe combined immunodeficiency (SCID) has attracted 
attention due to three main reasons: (a) being well-characterized, (b) knowing the mutations 
responsible for the disease, and (c) existing no other satisfactorily efficient treatment [3].
Independent of the type of applied gene therapy method, the therapy first identifies the 
mutant gene that causes the disease. Following that, the identical healthy gene (e.g., therapeu-
tic gene or transgene) is cloned. The therapeutic gene is designed according to the augment-
ing or suppressing or repairing needs. Since the penetration of “naked” oligonucleotides into 
cells is not probable, an appropriate carrier must be used in loading the produced therapeutic 
gene [4, 5]. This carrier is called vector and it is responsible for transporting the therapeutic 
gene to the patient’s target cell successfully. In this sense, a vector needs to come through 
the extracellular barriers and, then, the cellular barriers [6, 7]. Consecutive stages in gene 
therapy are given in Figure 1. The biggest challenge in a successful gene therapy is the issue of 
Hydroxyapatite - Advances in Composite Nanomaterials, Biomedical Applications and Its Technological Facets158
delivery. The optimal vector and the delivery system depend on the target cells and its char-
acteristics, duration of expression, and the size of the genetic material to be incorporated in 
the vector [8]. Therefore, an optimal delivery vector needs to be safe, particular, and efficient.
There are two main sorts of vectors used in the gene therapy: viral vectors and non-viral (or 
synthetic) vectors. Viral vectors are viruses that have been genetically mutated for transporting 
normal human DNA. Viruses have developed a way of encapsulating and transferring their 
genes to human cells in a pathogenic manner. This capability can be used in the manipulation 
of the viral genome to replace disease-causing genes with the therapeutic ones [9]. Among all 
vectors, viral vectors exhibit higher efficiencies for transfecting host cells. However, the immu-
nogenicity and the cytotoxicity are the two major drawbacks of using these carriers [10]. The 
first failure in the clinical trial of the related gene therapy was identified with the inflammatory 
response to the viral vector (Adenovirus). An additional and very important reason for the 
concerns over the employment of the viral vectors is the formation of insertional mutagenesis 
in which an exogenous DNA sequence integrates into the genome of a host organism. This can 
trigger the proliferation of oncogenes which leads to the malignant transformation of cells [8]. 
Therefore, non-viral vectors have the safety advantage over the viral vectors due to the demon-
strated reduced pathogenicity. However, due to low delivery efficiency, thus, poor expression 
of their transgenes, the applications of non-viral gene transfer were previously disregarded 
[8]. Since non-viral vectors have less immunotoxicity, they have been applied in clinical tri-
als from 2004 to 2013, whereas the use of viral vectors in the same treatments decreased sig-
nificantly, then. Applications of a variety of non-viral vectors entering clinical trials, increased 
because of the advances in their performance, selectivity, gene expression period, and safety 
characteristics [8]. For therapeutic purposes; DNA, mRNA and short double-stranded RNA, 
including small interfering RNA (siRNA) and microRNA (miRNA) mimics, can be delivered 
by using various non-viral vectors; however, there might be some drawbacks in the use of 
non-viral vectors in clinical trials. Figure 2 presents the barriers to achieve a successful in vivo 
delivery of nucleic acids using non-viral vectors [11]. The degradation caused by serum endo-
nucleases, the immune detection, the renal clearance from the blood, and the emerging non-
specific interactions are some of these handicaps and they need to be considered and avoided 
for a successful delivery. Furthermore, the carrier needs to extravasate from the bloodstream 
in order to reach the tissue targeted. Within the target tissue, it should mediate the cell entry 
and endosomal escape, as siRNA and miRNA mimics must be loaded into the RNA-induced 
silencing complex (RISC), whereas mRNA must bind to the translational machinery. DNA 
should be further transported to the nucleus to implement its activity [11].
Owing to their easy preparation and surface-functionalization, inorganic nanoparticles are 
promising non-viral vectors for gene therapy applications. If the nanoparticles are small 
enough (<100 nm), different nanoparticle materials such as calcium phosphates, polymers, 
Figure 1. Schematic illustration of consecutive stages in gene therapy.
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Figure 2. The barriers to success in vivo delivery of nucleic acids using non-viral vectors. Reprinted by permission from 
Macmillan Publishers Ltd.: [Nature Reviews Genetics] (13), copyright (2014).
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liposomes, silica, magnetite, carbon, clay, and gold can be employed as non-viral vectors [8]. 
Compared to rest of all nanoparticles, calcium phosphate (CaP) has several advantages because 
of its easy preparation [12], high chemical affinity toward DNA and RNA [13, 14], high bio-
compatibility, and good biodegradability properties in biological systems [12]. Further, CaP 
particles have the ability to enter the cell and breakdown in the cell, also addressing them as 
an appealing candidate among all other gene delivery vectors [1, 2].
3. Calcium phosphates
CaP is one of the major mineral constituents of all mammalian calcified tissues and it is bio-
compatible, biodegradable, non-toxic, and non-immunogenic [14], therefore, CaP has wide-
spread use in nanomedicine, including tissue engineering, imaging, and drug/gene delivery 
[14]. Furthermore, it can degrade into ions inside the early lysosomes of the cells, which 
makes it a convenient and safe intracellular delivery agent for the therapeutic small mol-
ecules and genes [14, 15]. Therefore, CaP nanoparticles have been widely used as non-viral 
vectors since the 1970s [16]. Negatively charged nucleic acids can bind to CaP nanoparticles 
with high affinity via calcium ion chelation and are consequently protected from degradation 
by endonucleases [14].
Hydroxyapatite (HA), with the formula Ca
10
(PO
4
)
6
(OH)
2
, has a Ca/P molar ratio of 1.67 and it is 
the most stable and least soluble phase of all calcium orthophosphates. Pure HA never forms in 
biological systems. Nevertheless, because of its excellent biocompatible, bioactive, and osteo-
conductive properties, HA is widely used in medical and dental applications, such as hard 
tissue repair, bone defect filling, bone regeneration, coatings of metal prostheses, and tumor 
surgery applications, etc. [17]. HA nanoparticles have recently been used in medical applica-
tions as carriers for growth factors, antibiotics, cancer drugs, antigens, and nucleic acids [18]. 
Moreover, HA columns are used for protein chromatography [19]. Several techniques, such 
as solid state, precipitation, sol-gel, hydrothermal, multiple emulsion, and biomimetic deposi-
tion have been used in the synthesis of HA nanoparticles [20]. However, some variability in 
the structure and morphology may occur depending on the synthesis method [21].
The non-stoichiometric apatites are of biological importance because they resemble mineral com-
ponent of bone, enamel, dentin, and cementum. Bone mineral is essentially calcium-deficient 
hydroxyapatite (CDHA, Ca10−x(HPO4)x(PO4)6−x(OH)2−x) with a Ca/P ratio of approximately 1.5. While CDHA is chemically and compositionally similar to beta-tricalcium phosphate (β-TCP), it 
exhibits structural similarity to stoichiometric HA [14]. CDHA exhibits high solubility in water 
or body fluids while high crystalline stoichiometric HA has poor solubility. Over a broad range 
of concentration, pH, and temperature, non-stoichiometric apatites can be synthesized by vari-
ous precipitation techniques [21].
3.1. The use of calcium phosphate nanoparticles for gene therapy
Although several studies have focused on the direct injection of naked DNA into various tis-
sues such as skeletal muscle, liver, thyroid, heart muscle, brain, and urological organs, sig-
nificantly (respectively) low transfection efficiencies were gained [22]. The literature indicates 
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that there are three general levels that non-viral CaP-DNA delivery systems operate: (a) DNA 
condensation and complexation, (b) endocytosis, and (c) nuclear targeting or entry [23]. Before 
introducing into the cell, negatively charged DNA is complexed with CaP nanoparticles. 
Because of its positive charge, CaP-DNA complex gets bound to the negatively charged cell 
membrane and is consequently received by the cells. For the uptake of macromolecules or 
nanoparticles, endocytosis as a frequent methodology can internalize non-viral gene delivery 
vectors [24]. Endocytosis can be defined as the penetration of the cell membrane which is 
followed by the incorporation into an intracellular vesicle [25]. After endocytosis, the vector-
DNA complex is mostly kept in perinuclear endosome/lysosomes. In case, DNA does not 
escape from the endosome, endosomal degradation of DNA might happen during endocyto-
sis. The acidic pH (5–5.5) of endosomes and lysosomes usually causes the decomposition of 
DNA captured inside the vectors [23]. For this reason, DNA transfection requires endosomal 
escape. The degradation of DNA by particular enzymes (nucleases) depends on an efficient 
release of DNA into the cytoplasm. There are some barriers needed to overcome for having a 
successful entry of DNA into the nucleus; hence, protection from the nucleases is required. In 
the next step, the DNA is introduced into the nucleus. Nuclear pore complexes (NPCs) make 
the transfer of molecules into the nucleus [10]. Even though NPCs are very permeable to small 
molecules, they restrict the movement of larger molecules across the nuclear envelope. For 
the purpose of eliminating this obstacle; first, macromolecules carrying a nuclear localization 
sequence (NLS) are recognized by importins, and next they are actively transported through 
the pore into the nucleus [10]. Furthermore, Ca2+ regulated transport involves intermediate-
sized molecules (10–70 kDa) and it does not entail an NLS [23]. Under conditions in which Ca 
is present in the cytosol (such as from CaP), the central plug is located well below the cytoplas-
mic ring of the NPC, and the pore can allow the diffusion of even medium-sized molecules. 
Under such circumstances, DNA-Ca complexes can easily enter the nucleus through the NPC.
The biochemistry field has been using the standard calcium phosphate transfection method, 
since it was first introduced by Graham and van der Eb in 1973 [26]. In many studies, cal-
cium and phosphate solutions are mixed in the presence of DNA and coprecipitated with 
DNA to form the transfection complex [27]. However, this technique allows for the formation 
of a heterogeneous size distribution of CaP-DNA complexes and induces a large deviation 
in the transfection efficiency. The control of the growth and thus the size of the CaP-DNA 
complex are the two important factors for developing DNA delivery systems [28]. The size 
of the complex can be regulated by adding organic or inorganic modifiers during the precipi-
tation process. Kakizava et al. [28] developed monodisperse CaP nanoparticles surrounded 
by hydrophilic polymer layer through complexation with poly(ethylene glycol)-block-
poly(aspartic acid) (PEG-PAA) via basic mixing of calcium/DNA and phosphate/PEG-PAA 
solutions. It was shown that the use of PEG and PAA is beneficial to obtain a narrow size 
distribution. The efficiency of the complex was determined by measuring the amount of DNA 
incorporated into the particles by using gel permeation chromatography and fluorescence 
measurements. Similarly, HA nanorods with a length of 100 nm and a diameter of 25 nm were 
synthesized by using a stabilizing block copolymer (PLGA–mPEG) and the DNA loading 
capacity was investigated [29]. In this study, first, HA nanorods were synthesized and then, 
the HA-DNA complex was obtained by quick mixing them together in the presence of CaCl
2
. 
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Plasmid DNA and salmon sperm DNA were used to test the DNA loading capacity and a 
huge enhancement of DNA binding capacity was observed. The strategy of using block copo-
lymer and post-binding of HA nanorods with DNA make them remarkably efficient and safe 
gene vector [29]. Zhu et al. [30] synthesized short HA nanorods with a length of 40–60 nm and 
then mixed them with EGFP-N1 pDNA to form the nanoparticle-DNA complex. The agarose 
gel electrophoresis showed that the HA nanorods potentially adsorb EGFP-N1 pDNA under 
acidic (pH = 2) and neutral (pH = 7) conditions. HA-EGFP-N1 pDNA complex was transfected 
to the SGC-7901 cells in vitro with the efficiency about 80%. Two weeks after tail vein injec-
tion into mice, no acute toxicity was revealed. The liver, the kidney, and the brain organ tissue 
specimen of the sacrificed mice were investigated via TEM after receiving the injection of 
pDNA complex. EGFP green fluorescence expression was observed, which suggested that the 
EGFP-N1-pDNA did effectively transport on the HA nanoparticles into these organ tissues 
and the pDNA did integrate into the cell genome and ultimately successfully expressed there.
In another study, CaP nanoparticles with varying calcium (Ca) to phosphate ion (P) ratios 
were synthesized and the effect of the Ca/P stoichiometry on controlling the particle size 
and the plasmid DNA binding efficiency was investigated [31]. The results indicated that the 
determination of the Ca/P ratio which optimizes both DNA binding and condensation can 
overcome many barriers associated with transporting the DNA into the nucleus and thus 
improve transfection efficiencies. The reported optimal size of the complex is about 25–50 nm 
which performed efficiently at both binding and condensing the plasmid DNA.
To obtain a better capturing of the DNA, substitute ions, such as Mg2+, CO
2
3, K+, and Al3+, can 
be added in CaP crystal lattice [32]. The studies concerning the effect of the substitute ions on 
the precipitation and the crystallization of HA and other CaPs are present in literature. It was 
reported that the integration of Mg2+ into the CaP lattice limits the particle growth and this 
leads to the formation of smaller sizes of CaP/DNA or CaP/siRNA precipitates, which resulted 
in remarkably enhanced cellular uptake. Chawdory et al. [33] reported that an increase in 
the dose of Mg2+ dramatically reduced the particle diameters and remarkably higher cellular 
uptake of DNA and its subsequent expression (N10-fold) was obtained compared with classi-
cal calcium phosphate coprecipitation [33].
Another strategy for improving the transfection efficiency is producing a multi-shell CaP-DNA 
complex, in which calcium phosphate core was coated with DNA, followed by calcium phos-
phate coating, and finally a second DNA coating [5, 34]. In this way, DNA can be better protected 
from enzymatic degradation and intracellular attack and therefore, a considerable increase in 
transfection efficiency can be obtained compared to single-shell CaP-DNA complex. It should be 
considered that the reaction temperature, the way of mixing, reagent concentration, pH, precipi-
tation time, and the time between precipitation and transfection are important for the efficiency 
of cell transfection [1, 5, 34].
To protect the therapeutic agent from the biological environment, CaP-DNA can be encapsu-
lated within a synthetic polymer such as polyethylene glycol, poly(methacrylic acid) or poly-
ethyleneimine. However, synthetic polymers such as polyethyleneimine (PEI) are cytotoxic 
and not suitable for the in vivo delivery of nucleic acids. The toxicity of PEI partly comes from 
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its limited biodegradability [35]. Klesing et al. [36] functionalized commercial hydroxyapatite 
nanorods with polyethyleneimine (PEI) and an average particle size of 190 nm without any 
agglomerates was obtained. In order to track the adsorption capacity of the HA-PEI nanorods, 
varying amounts of DNA was added to the dispersion and the dispersion stability was moni-
tored by dynamic light scattering. Varying amounts of EGFP encoding DNA were added to 
the HA–PEI nanorods for the transfection of HeLa and MG-63 cells. As the addition of DNA 
reduces the surface zeta potential of the cationic HA-PEI delivery system, the nanorods which 
have small amounts of DNA exhibit higher positive zeta potential and thus better cellular 
uptake by the negatively charged cell membrane.
Since the cell membrane is negatively charged, positively charged nanoparticles lead to the 
higher degree of internalization due to the ionic interactions occurring between positively 
charged particles and cell membranes [37, 38]. Furthermore, it was reported that the posi-
tively charged nanoparticles might escape from lysosomes if they are internalized and show 
perinuclear localization, while the negatively and neutrally charged nanoparticles colocal-
ized with lysosomes [39, 40]. The surface modification can strongly alter some characteristics 
of nanoparticles (e.g., hydrophilicity, hydrophobicity, and surface charge). Therefore, conju-
gating the nanoparticles with special functional groups can enhance the cellular uptake and 
thus the transfection efficiency of the delivery system. Recent research has revealed that argi-
nine with guanidyl group can facilitate the cellular uptake of covalently conjugated particles, 
although the uptake mechanism is still controversial [37]. Wang et al. [37] synthesized rod-like 
arginine functionalized HA (HA/Arg) nanoparticles with an average length of 50–90 nm and 
the DNA complex was prepared by mixing the HAp/Arg with plasmid DNA (pEGFP-N1). 
Transfection efficiency was tested on the HeLa cells which were treated with pEGFP-N1-HA/
Arg complex and the transfection efficiency increased after arginine modification.
In another study, it was reported that if two-dimensional layered materials are used as gene 
delivery materials, they exhibit desired functionalities [41]. Zuo et al. [41] prepared lamellar 
HA (L-HA) nanoplates with varying size and shape by changing the amount of the templat-
ing agent and precursor solutions. pDNA was added dropwise into L-HA suspensions with 
varying concentrations for the complex formation. It was suggested that pDNA loading is 
not only limited by the adsorption of the HA surface but also intercalation of pDNA into HA 
layers. Thus, a mouse fibroblast L929 cell line was used to investigate the gene transfection of 
pDNA/L-HA complexes. As the L-HA showed much better DNA loading capacity and trans-
fection yield, the great potential of the nanoplates with good lamellar structure was reported.
In summary, different strategies were developed for improving the gene transfection effi-
ciency by using CaP nanoparticles as non-viral vectors and some of the reported models are 
illustrated in Figure 3. Most of the approaches were focused on controlling the size and the 
shape by utilizing special agents during CaP synthesis or encapsulating the particle-DNA 
complex mostly in a proper layer of polymer to obtain positive surface charges.
3.2. The use of calcium phosphate nanoparticles for gene silencing
Small interfering RNA (siRNA) is a class of short, double-stranded RNA molecules of about 
21–25 nucleotides, which can mobilize the RNA interference (RNAi) pathway [14, 42]. RNA 
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interference (RNAi) effect is a sequence-specific gene-silencing process which is effectively 
applied for functional genomics, in vivo target validation, and gene-specific medicines. 
Similar to the antisense and ribozyme strategies, RNAi depends on complementarity between 
the RNA and its target mRNA for the destruction of the target gene [42].
When compared to conventional drugs or small molecules with a limited range of protein 
targets, siRNA may perhaps be used to interfere with the expression of nearly any gene tran-
script in a specific manner. Although siRNA-based RNAi technology has been launched as an 
effective methodology in treating several genetic diseases, this technology is limited owing 
to the degradation of siRNA in the nucleases [14]. Thus, a biocompatible carrier approach 
is necessary to overcome the barriers for the delivery of siRNAs for successful therapeutic 
applications [14].
Although both plasmid DNA and siRNA are similar double-stranded nucleic acids having 
anionic phosphodiester backbones and the same negative charge to nucleotide ratio, the use 
of DNA requires some different major aspects regarding its complex formation and its intra-
cellular delivery [39]. For being transcribed, plasmid DNA needs to cross the cytosol and 
reach the nucleus. Therefore, the delivery of plasmid DNA by using chemical delivery vec-
tors is sometimes ineffective on non-dividing quiescent cells due to the cell nucleus envelope 
barrier [42]. Further, the siRNA only requires to be delivered to the cytosol for initiating the 
silencing activity and the therapeutic potential of siRNAs has prompted a revival and strong 
research and development effort in this field.
In some studies, CaP is precipitated with siRNA to form the gene silencing complex. Sokolova 
et al. [5] investigated the efficiency of single-shell (the core of CaP, the shell of siRNA) and multi-
shell (the core of CaP, a first shell of siRNA, the second shell of CaP, the third and outermost 
Figure 3. Some of the CaP-DNA complex strategies reported in the literature.
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shell of siRNA) nanoparticles to inhibit the expression of intercellular enhanced green fluores-
cent protein (EGFP) in HeLa cells. Both single-shell and multi-shell nanoparticles have a spheri-
cal shape with a diameter of about 100–200 nm. The gene silencing efficiency is proportional 
to the extent of EGFP inhibition in the cells (cells which show no green fluorescence anymore) 
and determined by transmission light microscopy and fluorescence microscopy. Not only the 
concentration of oligonucleotides but also the nature of oligonucleotides (single- or double-
stranded) can affect the stability of the colloidal delivery system. Monodisperse colloids can be 
prepared with siRNA at a concentration of 45 mM. The relative gene silencing efficiencies of 
different delivery systems were investigated and high gene silencing efficiency was obtained 
for multi-shell nanoparticles in which siRNA is protected from intracellular degradation.
Although the use of CaP for siRNA delivery has performed a lot of promising progresses, the 
application of CaP-siRNA in clinical therapy is still far from satisfaction [31]. To improve the 
physical stability and the transfection efficiency of CaP nanoparticles, different strategies have 
been evaluated for the modification of CaP carriers. One of the most crucial factors of a suc-
cessful siRNA therapy is to control the size and the surface charge of the siRNA complex for 
ensuring the delivery and release of the therapeutic material into the target gene [31]. For this 
aim, some surface modifications including encapsulating the CaP-siRNA complex with dif-
ferent polymers or adding a stable polymer outer layer were reported [43]. In order to obtain 
better colloidal stability and to reduce protein adsorption, Polyethylene glycol (PEG), a neu-
tral and hydrophilic polymer, could be used [44]. It was reported that, compared with some 
commercially available transfection reagents, CaP-PEG nanoparticles reveals better serum 
tolerability. Owing to the decomposition of CaP nanoparticles under a cytosolic environment, 
calcium ion concentration increases. However, by using PEG as a shell on the CaP core, much 
lower calcium ion concentrations can be maintained and thus significant biological effects 
can be reached in cultured cell lines. Giger et al. [44] modified CaP nanoparticles with PEG-
alendronate (alendronate is a bisphosphonate used to treat osteoporosis) for siRNA delivery 
and it was reported that PEG-ALE could stabilize the nanoparticles better. The transfection 
efficiency of the nanoparticles was assessed with a model siRNA targeting the Bcl-2 protein 
which inhibits apoptosis and is overexpressed in several cancers. PEG-ALE-CaP-siRNA 
exhibited a strong silencing effect in vitro at both the mRNA and protein levels. The cellular 
trafficking study showed that PEG-ALE-CaP-siRNA internalized into cells relied largely on 
the clathrin-dependent endocytosis. They further used PEG-functionalized bisphosphonate 
(PEG-bp) to prepare bp-stabilized CaP nanoparticles with the size of 200 nm for gene delivery 
[45]. PEG-bp-CaP showed effectively and sustained transfection ability to cells in vitro with 
low toxicity. Zhang et al. [18] developed CaP nanomicellar carriers which can efficiently keep 
siRNA in their CaP inner core by using PEG for regulating the size of the nanoparticles, which 
facilitated the internalization of siRNA by cells. The nanoparticles exhibited a well-defined 
spherical shape with a diameter of 100 nm and the thickness of PEG shell is about 10 nm. To 
evaluate the gene-silencing efficiency, dual luciferase assay was applied to the nanoparticles 
having different PEG shell thicknesses. Compared to 15 kDa PEG, the samples prepared with 
12-kDa PEG showed better gene silencing efficiency. So, the difference in gene knockdown 
may stem from the difference in cellular uptake of the nanoparticles with different PEG shell 
thicknesses. Further, compared to the samples prepared at pH 8.0, the samples prepared at 
pH 7.5 showed higher gene knockdown levels under the same conditions.
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Polyethyleneimine (PEI), another hydrophilic polymer, can also be used as an outer layer of 
the CaP-siRNA complex. However, it should be noted the potential cytotoxicity may limit its 
gene or drug delivery-based clinical applications [35]. Although PEI is an efficient transfec-
tion agent for DNA due to its great endosomal escaping capability, PEI/siRNA complexes 
are highly unstable [46]. Nevertheless, some successfully in vitro siRNA delivery applica-
tions were reported by using PEI as a surface modifier. Klesing et al. [36] developed a cat-
ionic nucleic acid delivery system based on hydroxyapatite nanorods functionalized with a 
layer of PEI. For gene silencing, HeLa-EGFP cell line (a genetically modified transformed 
cervix epithelial cell line expressing the enhanced green fluorescent protein, EGFP) was used. 
Commercial carriers, Lipofectamine™ and PolyFect®, were also used for comparing the 
transfection efficiency of the CaP-PEI system. Gene silencing efficiency of hydroxyapatite–
PEI–siRNA nanoparticles on HeLa-EGFP cells was determined approximately 48–72 h after 
transfection by transmission light microscopy and fluorescence microscopy. The gene silenc-
ing efficiency of HeLa-EGFP cells was systematically determined for increasing amounts of 
added siRNA, up to a charge reversal by the anionic siRNA. The efficiency of gene silenc-
ing increased with higher amounts of siRNA, however, minimized at the point where par-
ticles agglomerated. By adding a PEI layer around the hydroxyapatite/PEI/siRNA, the charge 
reversed back to positive, resulting in even higher silencing rates.
To enhance the silencing efficiency, Neuhaus et al. [47] generated triple-shell CaP 
nanoparticles (CaP–siRNA–CaP–PEI) with an outer shell of PEI. PEI was used for the 
colloidal stabilization and to give the particles a positive charge. Tumor necrosis factor α 
(TNF-α), which is a pro-inflammatory cytokine, was silenced by treating LPS-stimulated 
MODE-K cells with triple-shell CaP nanoparticles. MODE-K cells are a murine epithelial 
cell line from the intestine and serve as a model for intestinal epithelial cell function. In 
this study, the gene silencing efficiency was first demonstrated with HeLa–EGFP cells by 
three different methods: cell counting by using fluorescence microscopy, fluorescence-
activated cell sorting (FACS) analysis, and quantitative real-time PCR (qPCR). The silenc-
ing efficiency by fluorescence microscopy was difficult to interpret. More accurate results 
were obtained by FACS analysis and qPCR. qPCR results show enhanced silencing effects 
with the increasing amount of siRNA. By introducing triple-shell CaP nanoparticles into 
MODE-K cells, the expression of TNF-α was strongly downregulated. Gene silencing effi-
ciencies close to results with the commercial agent Lipofectamine were achieved. Thus, 
CaP nanoparticles are well suited to reduce inflammatory reactions by silencing the cor-
responding cytokines, e.g., TNF-α.
In most of the studies, siRNA was precipitated together with calcium and phosphor precur-
sor solutions for obtaining core-shell delivery complexes.  Therefore, the particles were only 
characterized in terms of particle size and surface charges, while it was not determined if the 
particles were hydroxyapatite or other CaP phases. However, according to the current state of 
knowledge; particle size, particle shape, surface charge, and crystallinity may have an effect on 
the siRNA binding capacity and thus the efficiency of cellular uptake. For this reason, Bakan 
et al. [14] synthesized spherical-like hydroxyapatite (HA-s), needle-like hydroxyapatite (HA-
n), and calcium deficient hydroxyapatite (CDHA), and the particle characteristics were inves-
tigated in detail. The effects of particle size, particle shape, crystallinity, and surface charge 
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on the binding capacity of two different siRNAs were investigated. Arginine functionalized 
needle-like HA nanoparticles with a diameter of 15 nm and a length of 100–150 nm provided 
the best binding behavior for siRNA among the others, due to the high positive zeta potential 
and the geometry factor of the particles. Needle-like HA nanoparticles have also a much larger 
surface to volume ratio, hence, the surface area of the Ca2+ rich plane, which is considered to 
be positively charged, is higher than the others. Therefore, the binding efficiency of HA-n 
is higher than HA-s. Although CDHA has similar geometry to HA-n with almost the same 
dimensions, the binding potential of CDHA is lower than HA-n due to the deficiency of posi-
tive charged Ca2+. Additionally, the nanoparticles without any functionalization also exhibited 
considerable affinity to the siRNAs.
3.3. The use of calcium phosphate nanoparticles for in vivo gene silencing
The success of in vitro siRNA therapy has been demonstrated by inhibiting the expression 
of many different genes and in many different cell types [48]. However, siRNA delivery to 
animal tissues requires considering some physical, chemical, and biological complicated 
processes [48]. There are some important weaknesses that limit the extensive application 
of several delivery systems such as the mutagenesis or oncogenesis potential, host immune 
responses, and high cost. As the immune response toward the non-viral siRNA delivery sys-
tems is very few, this yields an advantage in drug target validation and permits the therapeu-
tic applications of siRNA [49].
CaCl
2
-modified HA nanoparticles were used as a non-viral vector in the in vivo delivery of 
si-Stat3 plasmid-based siRNA for suppressing the mouse prostate tumor growth and pro-
moting apoptosis of cancer cells [49]. Stat3 is a transcription factor and has been found in an 
activated state in numerous primary tumors and the Stat3 signaling pathway can be used as a 
potential target for antitumor therapy. The levels of Stat3 mRNA and protein were downreg-
ulated in cancer tissues after si-Stat3 treatment, indicating that HA can deliver Stat3-specific 
siRNA into cancer cells, resulting in the inhibition of Stat3 expression.
The effect of HA-siRNA complex on chronic inflammatory pain was investigated in vivo in 
mice [50]. HA nanorods with a length of 40–50 nm were synthesized by a chemical precipi-
tation-hydrothermal technique for the delivery of siRNA. NR2B, the target gene, is a NMDA 
receptor subunit which plays an important role in the adjustment of chronic pain. To obtain 
HA-NR2B-siRNA complex, HA nanoparticle suspension was mixed with siRNA under dif-
ferent pH conditions. The results show that HA nanoparticles can bind to siRNA effectively 
in the acidic or neutral condition at an HA: siRNA mass ratio of 35:1 or higher. In addition, 
HA-NR2B-siRNA complex remains stable in the physiological condition. HA-siRNA com-
plex was injected into subarachnoid space of each mice. On the seventh day after injection, 
1% formalin solution was injected into the plantar surface of the right hind paw for the forma-
lin test. The contralateral paw served as control. Pain scores were given and the Time-Score 
Curves were plotted. Via intrathecal injection, HA-siRNA complex can significantly reduce 
formalin-induced nociception in the tonic phase in mice. Therefore, HA may have a potential 
as an effective siRNA carrier even in in vivo.
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In another study, multi-shell CaP nanoparticles (CaP-siRNA) encapsulated into poly(D,L-
lactide-co-glycolide) (PLGA) and a final layer of polyethyleneimine (PEI) for the local thera-
peutic treatment of colonic inflammation [51]. The synthesis of nanoparticles was performed 
via rapid mixing of equal amounts of calcium-L-lactate and diammonium hydrogen phos-
phate aqueous solutions. Right after mixing, the CaP dispersion was mixed with siRNA and 
then encapsulated into PLGA. The freeze-dried nanoparticles were afterward resuspended 
in an aqueous solution of PEI. PLGA allows for a controllable releasing behavior which can 
be affected by the geometry and the molecular weight of the nanoparticles [51]. PEI was 
employed as a shell layer to provide a positive surface charge to the encapsulated nanopar-
ticles. siRNA-loaded nanoparticles could be effectively delivered into the cytoplasm of epi-
thelial cells and immune cells of mice in vivo and thus induce active gene silencing. Such 
a treatment induced a significant reduction of the target genes (TNF-α, IP-10, and KC) in 
colonic biopsies and mesenteric lymph nodes when they were accompanied with a distinct 
amelioration of intestinal inflammation. Thus, this study provides a promising approach for 
the treatment of intestinal inflammation via CaP/PLGA-siRNA nanoparticles.
3.4. Calcium phosphate nanoparticles for miRNA delivery
MicroRNAs (miRNAs; miRs) are single-stranded, non-coding RNA molecules which are bio-
chemically and functionally indistinguishable from siRNAs [52]. It is known that miRNA can 
bind to the target mRNA and inhibits its expression [52]. Although the functions of miRNAs 
have not quite known yet, the role of miRNA in the regulation of gene expression by con-
trolling the various cellular and metabolic pathways was revealed. When a single miRNA is 
able to regulate several mRNA targets, multiple miRNAs are cooperatively able to regulate a 
single mRNA target [53].
As similar to siRNA applications, the major challenge of miRNA therapy is delivering the 
miRNA to the target tissue efficiently [54]. The nucleases (e.g., serum RNase A-type nucleases 
in the blood) can degrade naked miRNAs within seconds, therefore, employing a sophisti-
cated carrier is crucial to enhance the intracellular delivery and provide an endosomal escape 
[54]. Current non-viral technologies used Lipofectamine®2000, PEG or PEI as a carrier for 
the protecting of miRNAs [55]. However, CaPs are a promising alternative to polymers or 
synthetic lipids with having better biocompatibility and the ease of use [55]. Manipulation of 
gene expression by using microRNAs (miRNAs) offers remarkable and promising potential 
for the field of tissue engineering [55]. Nevertheless, the deficiency of adequate site-specific 
and bioactive carriers has limited the clinical translation of miRNA-based therapies. For this 
purpose, Castano et al. [55] developed a novel non-viral delivery complex by combining HA 
nanoparticles with reporter miRNAs (nanomiRs). To investigate the transfection efficiency of 
this complex, human mesenchymal stem cells (hMSCs) which are defined as a particularly 
hard cell type to efficient transfection was used. The results demonstrate that HA nanopar-
ticles combined with miR-mimics and antagomiRs resulted in high cellular internalization in 
monolayer hMSCs with limited cytotoxicity and both nanomiR-mimics and nanoantagomiRs 
provided continuous interference of greater than 90% in monolayer over 7 days. Although 
the efficient intracellular internalization generally requires positively charged particles of less 
Gene Delivery by Hydroxyapatite and Calcium Phosphate Nanoparticles: A Review of Novel and…
http://dx.doi.org/10.5772/intechopen.71062
169
than 200 nm, negatively charged HA-miRNA complexes with approximately 300 nm size 
provided high cellular internalization in accordance with the related literature [55].
Mauro et al. [56] investigated the potential of negatively charged CaP nanoparticles as a thera-
peutic system for the intracellular delivery of miRNAs to the cardiac tissue. In this study, 
CaP nanoparticles were synthesized using citrate as a stabilizing agent and crystal growth 
regulator. During the CaP synthesis, different amounts of synthetic unmodified and unpro-
tected miRNA duplexes (ranging from 1 to 10 μg ml−1) were added to the reaction medium. 
Although the size of CaP-miRNAs increased with the increasing amount of miRNA, the PDI 
values and surface charges stayed close to those of miRNA-free nanoparticles. To evaluate 
the efficiency of miRNA delivery, HL-1 cells were exposed to CaP-miRNAs both in vivo 
and in vitro and the intracellular levels of miRNAs were measured at different times after 
the transaction. The results show that CaP nanoparticles can be successfully penetrated into 
cardiomyocytes without increasing toxicity or mediating with any functional properties and 
synthetic microRNAs can be successfully encapsulated within CaP nanoparticles.
In summary, it was revealed that both positively and negatively charged HA nanoparticles 
have the potential to complex with both miR-mimics and antagomiRs for forming nanomiRs, 
and they have a tremendous capability to maintain a successful internalization. Therefore, 
HA nanoparticles can be employed as a delivery system for the clinical translation of miRNA-
based therapies.
4. Conclusion
The yield of gene therapy generally relies on the performance of the carrier vector. Because of 
the high efficiency of viral vectors in gene therapy, their use has been prevailing so far in the 
clinical trials. However, their potential immunogenicity, cytotoxicity, and mutagenesis risks are 
the major drawbacks of using them. Therefore, the use of a variety of non-viral vectors entering 
clinical trials is because of the advances in their efficiency, specificity, gene expression duration, 
and safety characteristics. In order to design bio-adaptable non-viral vectors, mechanisms of 
transfection, from complex formation to intracellular delivery, have to be well-understood. In 
the gene delivery process through of non-viral vectors, there have been potential rate-limiting 
stages such as, cell membrane interaction efficiency, internalization, endosomal escape, gene 
release from intracellular compartments and the transcription into the nucleus. Each of the 
aforementioned stages has to be determined by examining the characteristics at the molecular 
level for coming through the sorted limitations. Clinical achievement is still beyond the ideal 
conditions despite the fact that non-viral vectors can be applied efficiently for in vitro trials. 
Promisingly, advances in novel technologies for the development of these carriers allow many 
research groups for studying in vitro and in vivo behaviors of non-viral vectors for gene therapy.
Calcium phosphates (CaPs) are the main mineral constituents of biological hard tissues. 
Except for enamel, they are always found as nanoparticles. Due to their excellent features, 
they have widespread use as a bionanomaterial in the fields of nanomedicine, including 
 tissue  engineering, imaging, and drug/gene delivery. They are biocompatible, biodegradable, 
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non-toxic, and non-immunogenic. Moreover, its characteristic degradation into ions is pres-
ent in all cells and extracellular fluids make it a safe and suitable intracellular delivery sys-
tem for therapeutic small molecules and genes. CaP nanoparticles have been widely used in 
non-viral gene delivery systems since the 1970s. Negatively charged nucleic acids can bind to 
CaP nanoparticles with high affinity by calcium ion chelation and are consequently protected 
from degradation by endonucleases. During internalization, continuous acidification in the 
lysosomes causes degradation of CaP particles and the therapeutic molecules can be released. 
Nevertheless, the cytotoxicity may slightly increase owing to the rise in the level of intracel-
lular calcium which is caused by this degradation. In the literature, it has been reported that 
a large spectrum of CaP nanoparticles has been synthesized and employed as a carrier for 
DNA, siRNA, and miRNA. In most of the studies, CaP-nucleic acid complex was obtained 
by quick mixing of calcium precursor solution with DNA/siRNA which is followed by add-
ing the phosphate solution. Since the nucleation and crystal growth can be influenced by the 
precipitation parameters such as pH, concentrations of each solution and temperature and 
also, cell transfection efficiency may be drastically affected by similar conditions. The time slot 
between precipitation and transfection also influences the transfection efficiency in terms of 
colloidal stability of the complex. The efficiency of transfection has been found to be cell-type 
dependent and intercellular trafficking pathways. If DNA/siRNA is surrounded by an addi-
tional shell of calcium phosphate, it can be better protected from enzymatic degradation and 
intracellular attack by nucleases. Core-shell structure leads to a significant enhancement in 
the transfection or silencing efficiencies compared to single-shell calcium phosphate nanopar-
ticles. It should also be noted that the surface charge of the complex has a significant effect on 
the penetration through the cell membrane. Due to the surface-exposed phospholipids, the cell 
membrane is negatively charged and positively charged particles are taken up by the mem-
brane at a higher rate compared to negatively charged ones. For having positively charged 
CaPs, surface modification strategies including amino acid functionalization, surface coating 
with cationic or neutral polymers were carried out. Recent research has indicated that the 
modification of CaP nanoparticles by mostly coating a suitable polymer, provides a better 
colloidal stability and thus improves not only in vitro but also in vivo gene transfection or 
silencing efficacy compared to using bare CaP nanoparticles. The amount of the therapeutic 
materials largely depends on the carrier adsorption potential and this drastically affects the 
surface charge of the complex; therefore, the higher the amount of DNA or siRNA does not 
bring about the higher transfection or silencing efficiency. To have a better understanding of 
the effect of carrier shape on cellular uptake and cytotoxicity, various studies have been carried 
out and reported in the literature. It was found that the cytotoxicity of the particles not only 
depends on the particle shape but also it can be cell-type dependent and the mechanisms that 
induce cytotoxicity through particle-cell association, whether arising from ROS generation, 
cytokine production or cellular uptake, are still not clear.
The effects of chemical, physical, and/or biological aspects generally make in vivo DNA or 
siRNA delivery complicated for animal tissues. The limitations in the use of most delivery 
systems in vivo can be summarized as responses of host immune, the risk of mutagenesis 
or oncogenesis and high costs. Considering CaP nanoparticles as non-viral vectors are still 
to be questioned for clinical trials. The increase in the level of the solution’s ion strength, for 
instance, might cause a decrease in the electrostatic repulsion between nanoparticles and this 
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might result in agglomeration. In the presence of proteins, hydrophilicity, surface chemistry, 
and the charge of the nanoparticles can be altered due to adsorption of proteins on their sur-
face. Accordingly, the behavior of a functionalized nanoparticle will be different in the tissue 
or the bloodstream compared to aqueous medium or physiologic solutions. This case leads 
to complications which are difficult to handle in the clinical trials. Nanoparticles have com-
pletely different biological properties when compared to their bulk properties and therefore 
all aspects are to be considered carefully for maintaining appropriate colloid stability and cel-
lular interaction behavior. In the modified nanoparticles, the physicochemical state becomes 
more complex and this leads to less predictable biological responses and the cytotoxicity of 
the modified systems are also to be considered.
Bringing together all outcomes of the recent research, it can be concluded that the use of 
CaPs as non-viral vectors prevails among other non-viral vectors owing to their low-cost and 
safety behavior, as well as they exhibit better performance in overcoming the limitations that 
have been observed in other vectors. Providing that the size of the delivery complex is small 
enough, the surface charge of the complex permits maximum cellular internalization and the 
therapeutic molecules are protected through the cellular uptake; a successful transfection can 
be achieved and CaP nanoparticles can be defined as “second generation non-viral vectors” 
as Maitra [23] denoted.
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[7] Gascón AR, del Pozo-Rodríguez A, Solinís MA. Non-Viral Delivery Systems in Gene 
Therapy, Gene Therapy - Tools and Potential Applications, Dr. Francisco Martin (Ed.), 
InTech: Rijeka, Croatia. 2013. DOI: 10.5772/52704
[8] Ramamoorth M, Narvekar A. Non-viral vectors in gene therapy—An overview. Journal 
of Clinical and Diagnostic Research. 2015;9(1):1-6
[9] Robbins PD, Ghivizzania SC. Viral vectors for gene therapy. Pharmacology and Thera-
peutics. 1998;80(1):35-47
[10] Sokolova V, Epple M. Inorganic nanoparticles as carriers of nucleic acids into cells. Ange 
wandte Chemie International Edition. 2008;47(8):1382-1395
[11] Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors 
for gene-based therapy. Nature Reviews Genetics. 2014;15(8):541-555
[12] Dorozhkin SV, Epple M. Biological and medical significance of calcium phosphates. 
Angewandte Chemie International Edition. 2002;41(17):3130-3146
[13] Okazaki M, Yoshida Y, Yamaguchi S, Kaneno M, Elliott JC. Affinity binding phenomena 
of DNA onto apatite crystals. Biomaterials. 2001;22(18):2459-2464
[14] Bakan F, Kara G, Cokol Cakmak M, Cokol M, Denkbas EB. Synthesis and characteriza-
tion of amino acid-functionalized calcium phosphate nanoparticles for siRNA delivery. 
Colloids and Surfaces B: Biointerfaces. 2017;158:175-181
[15] Khan MA, VM W, Ghosh S, Uskokovic V. Gene delivery using calcium phosphate 
nanoparticles: Optimization of the transfection process and the effects of citrate and poly 
(L-lysine) as additives. Journal of Colloid and Interface Science. 2016;471:48-58
[16] Zhang J, Sun X, Shao R, Liang W, Gao J, Chen J. Polycation liposomes combined with 
calcium phosphate nanoparticles as a non-viral carrier for siRNA delivery. Journal of 
Drug Delivery Science and Technology. 2015;30:1-6
Gene Delivery by Hydroxyapatite and Calcium Phosphate Nanoparticles: A Review of Novel and…
http://dx.doi.org/10.5772/intechopen.71062
173
[17] Turkez H, Yousef MI, Sonmez E, Togar B, Bakan F, Sozio P, Stefano AD. Evaluation of 
cytotoxic, oxidative stress and genotoxic responses of hydroxyapatite nanoparticles on 
human blood cells. Journal of Applied Toxicology. 2014;34(4):373-379
[18] Zhang M, Ishii A, Nishiyama N, Matsumoto S, Ishii T, Yamasaki Y, Kataoka K. PEGylated 
calcium phosphate nanocomposites as smart environment-sensitive carriers for siRNA 
delivery. Advanced Materials. 2009;21(34):3520-3525
[19] Freitag R, Vogt S, Modler M. Thermoreactive displacers for anion exchange and hydroxy-
apatite displacement chromatography. Biotechnology Progress. 1999;15(3):573-576
[20] Bakan F, Lacin O, Sarac H. A novel low temperature sol–gel synthesis process for ther-
mally stable nano crystalline hydroxyapatite. Powder Technology. 2013;233:295-302
[21] Girija EK, Kumar GS, Thamizhavel A, Yokogawa Y, Kalkura SN. Role of material pro-
cessing on the thermal stability and sinterability of nanocrystalline hydroxyapatite. 
Powder Technology. 2012;225:190-195
[22] Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. Direct gene 
transfer into mouse muscle in vivo. Science. 1990;247(4949 Pt 1):1465-1468
[23] Maitra A. Calcium phosphate nanoparticles: Second-generation nonviral vectors in gene 
therapy. Expert Review of Molecular Diagnostics. 2005;5(6):893-905
[24] Khalil IA, Kogure K, Akita H, Harashima H. Uptake pathways and subsequent intracel-
lular trafficking in nonviral gene delivery. Pharmacological Reviews. 2006;58(1):32-45
[25] Yameen B, Choi WI, Vilos C, Swami A, Shi J, Farokhzad OC. Insight into nanoparticle cel-
lular uptake and intracellular targeting. Journal of Controlled Release. 2014;190:485-499
[26] Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adeno-
virus 5 DNA. Virology. 1973;52(2):456-467
[27] Welzel T, Radtke I, Meyer-Zaika W, Heumann R, Epple M. Transfection of cells with 
custom-made calcium phosphate nanoparticles coated with DNA. Journal of Materials 
Chemistry. 2004;14(14):2213-2217
[28] Kakizawa Y, Miyata K, Furukawa S, Kataoka K. Size-controlled formation of a calcium 
phosphate-based organic-inorganic hybrid vector for gene delivery using poly(ethylene 
glycol)-block-poly(aspartic acid). Advanced Materials. 2004;16(8):699-702
[29] Wu GJ, Zhou LZ, Wang KW, Chen F, Sun Y, Duan YR, Zhu YJ, Gu HC. Hydroxylapatite 
nanorods: An efficient and promising carrier for gene transfection. Journal of Colloid 
and Interface Science. 2010;345(2):427-432
[30] Zhu SH, Huang BY, Zhou KC, Huang SP, Liu F, Li YM, Xue ZG, Long ZG. Hydroxyapatite 
nanoparticles as a novel gene carrier. Journal of Nanoparticle Research. 2004;6(2):307-311
[31] Olton D, Li J, Wilson ME, Rogers T, Close J, Huang L, Kumta PN, Sfeir C. Nanostructured 
calcium phosphates (nanoCaPs) for non-viral gene delivery: influence of the synthesis 
parameters on transfection efficiency. Biomaterials. 2007;28(6):1267-1279
Hydroxyapatite - Advances in Composite Nanomaterials, Biomedical Applications and Its Technological Facets174
[32] Uskokovic V, Uskokovic D. Nanosized hydroxyapatite and other calcium phosphates: 
Chemistry of formation and application as drug and gene delivery agents. Journal of 
Biomedical Materials Research B: Applied Biomaterials. 2011;96 B(1):152-191
[33] Chowdhury EH, Kunou M, Nagaoka M, Kundu AK, Hoshiba T, Akaike T. High-
efficiency gene delivery for expression in mammalian cells by nanoprecipitates of 
Ca–Mg phosphate. Gene. 2004;341:77-82
[34] Sokolova VV, Radtke I, Heumann R, Epple M. Effective transfection of cells with multi-
shell calcium phosphate-DNA nanoparticles. Biomaterials. 2006;27(16):3147-3153
[35] Xu X, Li Z, Zhao X, Keen L, Kong X. Calcium phosphate nanoparticles-based systems for 
siRNA delivery. Regenerative Biomaterials. 2016;3(3):187-195
[36] Klesing J, Chernousova S, Epple M. Freeze-dried cationic calcium phosphate nanorods 
as versatile carriers of nucleic acids (DNA, siRNA). Journal of Materials Chemistry. 
2012;22(1):199-204
[37] Wang GH, Zhao YZ, Juan TAN, Zhu SH, Zhou KC. Arginine functionalized hydroxy-
apatite nanoparticles and its bioactivity for gene delivery. Transactions of Nonferrous 
Metals Society of China. 2015;25(2):490-496
[38] Gratton SE, Ropp PA, Pohlhaus PD, Luft JC, Madden VJ, Napier ME, DeSimone JM. The 
effect of particle design on cellular internalization pathways. Proceedings of the National 
Academy of Sciences. 2008;105(33):11613-11618
[39] Rabinovich-Guilatt L, Couvreur P, Lambert G, Dubernet C. Cationic vectors in ocular 
drug delivery. Journal of Drug Targeting. 2004;12(9-10):623-633
[40] Vasir JK, Labhasetwar V. Quantification of the force of nanoparticle–cell membrane 
interactions and its influence on intracellular trafficking of nanoparticles. Biomaterials. 
2008;29(31):4244-4252
[41] Zuo G, Wan Y, Meng X, Zhao Q, Ren K, Jia S, Wang J. Synthesis and characterization of a 
lamellar hydroxyapatite/DNA nanohybrid. Materials Chemistry and Physics. 2011;126(3): 
470-475
[42] Scherman D, Rousseau A, Bigey P, Escriou V. Genetic pharmacology: Progresses in siRNA 
delivery and therapeutic applications. Gene Therapy. 2017;24(3):151-156
[43] Escriou V, Carrière M, Bussone F, Wils P, Scherman D. Critical assessment of the nuclear 
import of plasmid during cationic lipid-mediated gene transfer. The Journal of Gene 
Medicine. 2001;3(2):179-187
[44] Giger EV, Castagner B, Räikkönen J, Mönkkönen J, Leroux JC. siRNA transfection 
with calcium phosphate nanoparticles stabilized with PEGylated chelators. Advanced 
Healthcare Materials. 2013;2(1):134-144
[45] Giger EV, Puigmartí-Luis J, Schlatter R, Castagner B, Dittrich PS, Leroux JC. Gene delivery 
with bisphosphonate-stabilized calcium phosphate nanoparticles. Journal of Controlled 
Release. 2011;150(1):87-93
Gene Delivery by Hydroxyapatite and Calcium Phosphate Nanoparticles: A Review of Novel and…
http://dx.doi.org/10.5772/intechopen.71062
175
[46] Devarasu T, Saad R, Ouadi A, Frisch B, Robinet E, Laquerrière P, Voegel JC, Baumert T, 
Ogier J, Meyer F. Potent calcium phosphate nanoparticle surface coating for in vitro and 
in vivo siRNA delivery: A step toward multifunctional nanovectors. Journal of Materials 
Chemistry B. 2013;1(36):4692-4700
[47] Neuhaus B, Frede A, Westendorf AM, Epple M. Gene silencing of the pro-inflammatory 
cytokine TNF-α with siRNA delivered by calcium phosphate nanoparticles, quantified 
by different methods. Journal of Materials Chemistry B. 2015;3(36):7186-7193
[48] PY L, Xie F, Woodle MC. In vivo application of RNA interference: From functional 
genomics to therapeutics. Advances in Genetics. 2005;54:115-142
[49] Liang ZW, Guo BF, Li Y, Li XJ, Li X, Zhao LJ, Gao LF, Yu H, Zhao XJ, Zhang L, Yan 
BX. Plasmid-based Stat3 siRNA delivered by hydroxyapatite nanoparticles suppresses 
mouse prostate tumour growth in vivo. Asian Journal of Andrology. 2011;13(3):481-486
[50] Yang H, Huang D, Zhu SH, Yan XB, Gu YH, Hui YXB, Gu YH, Yan H, Wu LX. Preparation 
and application of hydroxyapatite (HA) nanoparticles/NR2B-siRNA complex. Trans-
actions of Nonferrous Metals Society of China. 2008;18(4):913-918
[51] Frede A, Neuhaus B, Klopfleisch R, Walker C, Buer J, Müller W, Epple M, Westendorf 
AM. Colonic gene silencing using siRNA-loaded calcium phosphate/PLGA nanopar-
ticles ameliorates intestinal inflammation in vivo. Journal of Controlled Release. 2016; 
222:86-96
[52] MacFarlane LA, Murphy PR. MicroRNA: Biogenesis, function and role in cancer. Current 
Genomics. 2010;11(7):537-561
[53] Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 2004;116(2): 
281-297
[54] Chen Y, Gao DY, Huang L. In vivo delivery of MiRNAs for cancer therapy: Challenges 
and strategies. Advanced Drug Delivery Reviews. 2015;81:128-141
[55] Castaño IM, Curtin CM, Shaw G, Murphy JM, Duffy GP, O'brien FJ. A novel collagen-
nanohydroxyapatite microRNA-activated scaffold for tissue engineering applications 
capable of efficient delivery of both miR-mimics and antagomiRs to human mesenchy-
mal stem cells. Journal of Controlled Release. 2015;200:42-51
[56] Di Mauro V, Iafisco M, Salvarani N, Vacchiano M, Carullo P, Ramírez Rodríguez GB, 
Patrício T, Tampieri A, Miragoli M, Catalucci D. Bioinspired negatively charged calcium 
phosphate nanocarriers for cardiac delivery of microRNAs. Nanomedicine. 2016;11(8): 
891-906
Hydroxyapatite - Advances in Composite Nanomaterials, Biomedical Applications and Its Technological Facets176
